Our aims

Lynch syndrome is the most common inherited cancer syndrome affecting 1:280 individuals and enhancing the lifetime risk for several malignancies, most commonly for bowel and uterus cancer. However, despite generally elevated cancer risk in Lynch syndrome, not all Lynch syndrome carriers develop tumors during their life. Identification of factors influencing cancer risk in Lynch syndrome is of major clinical importance for precise risk estimation and prevention/treatment design for Lynch syndrome carriers. We aim to find out, whether the risk of developing a tumor could depend on one of the essential host factors, namely HLA type of the individual, and to delineate the HLA type-related cancer risk of Lynch syndrome carriers.